| Systematic (IUPAC) name | |
|---|---|
| (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethylpyridin-3-yl)-2-(morpholin-4-yl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]piperazine-2,5-dione | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | Non-regulated |
| Identifiers | |
| CAS number | 872599-83-2 1159097-48-9 (besylate) |
| ATC code | None |
| Chemical data | |
| Formula | C30H38N4O4 |
| Mol. mass | 518.6 g/mol |
Epelsiban (GSK-557,296-B) is a drug which acts as an non-peptide oxytocin receptor antagonist, and is being developed by GlaxoSmithKline for the treatment of premature ejaculation in men.[1][2]
|
||||||||||||||||||||||||||||||||